Close

Pharma Companies Support Antibiotic Waste Control Measures

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

BSI, a UK standards body, introduced a new certification called the Minimized Risk of Antimicrobial Resistance (AMR) to promote responsible antibiotic manufacturing in the global pharmaceutical supply chain. This certification, released in June 2022, is built upon the Antibiotic Manufacturing Standard.

The Minimized Risk of Antimicrobial Resistance (AMR) certification encourages responsible pharmaceutical manufacturing, safeguarding the natural environment, and slowing down antimicrobial resistance. This certification entails independent third-party verification to ensure that pharmaceutical companies effectively control waste streams containing antibiotic-active pharmaceutical ingredients (API) and drug products throughout manufacturing.

How does the Antimicrobial Resistance certification work?

The certification program involves an initial evaluation of compliance with the standard’s requirements, followed by annual surveillance to ensure the ongoing maintenance of appropriate controls. Once launched, all antibiotic manufacturers worldwide will be eligible to get this certification.

The pilot program supports efforts to control antibiotic waste

Leading pharmaceutical companies, including Pfizer, Roche, Sandoz, and Teva, are participating in a pilot program to provide independent evidence of their compliance with the Antibiotic Manufacturing Standard for selected antibiotics. These companies aim to be the first to achieve certification in the market.

Pfizer, among other participants, expressed enthusiasm for taking part in the pilot program and contributing to the appropriate control of antimicrobial manufacturing waste. They also anticipate the widespread adoption of this certification across the pharmaceutical industry. The companies involved in the pilot, in partnership with BSI and the AMR Industry Alliance, are actively supporting the development of the technical assessment process. They have also shown interest in obtaining the certification themselves and are strongly encouraging their supply chain partners to do the same.

The World Health Organization (WHO) considers AMR as one of the top 10 public health threats worldwide. In 2019, an estimated 4.95 million deaths were attributed to bacterial AMR.

Latest stories